

Reference:	FOI.16753.25
Subject:	Treatment of inflammatory diseases
Date of Request:	5 March 2025

Your request and our response

1. How many patients were treated with the following drugs from the following departments (for any disease) from the start of Oct 2024 to the end of Dec 2024?
Please use the latest available 3 months if Oct to Dec is not available and specify which 3 months has been used.

Hywel Dda University Health Board (UHB) provides, within the table below, the number of Dermatology, Gastroenterology and Rheumatology patients, treated with the listed medications, for any disease, during the period 1 October to 31 December 2024.

Where the figures in the table have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab	72	151	269
Apremilast	8	0	25
Bimekizumab	*	0	0
Brodalumab	*	0	0
Certolizumab Pegol	*	0	41
Deucravacitinib	0	0	0
Etanercept	*	0	198
Guselkumab	0	0	0
Infliximab (Remicade)	0	0	0
Infliximab (Biosimilars)	*	93	13
Ixekizumab	*	0	8
Risankizumab	24	34	0
Secukinumab	38	0	52
Tildrakizumab	*	0	0
Ustekinumab	18	120	8
Upadacitinib	7	36	23
Vedolizumab	0	109	*
Filgotinib	0	11	*
Golimumab	*	0	33
Mirikizumab	0	*	0
Ozanimod	0	*	0

Etrasimod	0	0	0
Tofacitinib	0	0	*
Baricitinib	0	0	58
Rituximab	0	*	27
Sarilumab	0	0	7
Tocilizumab	0	0	91

2. How many patients were treated with Ustekinumab and its biosimilars from the following departments (for any disease) from the start of Oct 2024 to the end of Dec 2024?
Please use the latest available 3 months if Oct to Dec is not available and specify which 3 months has been used.

The UHB provides, within the table overleaf, the number of Dermatology, Gastroenterology and Rheumatology patients who were treated with Ustekinumab and its biosimilars, for any disease, during the period 1 October to 31 December 2024.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Ustekinumab (Stelara)	*	62	*
Ustekinumab (Pyzchiva)	0	0	0
Ustekinumab (Uzpruvo)	18	80	8
Ustekinumab (Wezenla)	0	0	0

3. How many patients were treated with Stelara and its biosimilars (for any disease) in the months Oct 2024, Nov 2024, and Dec 2024?
Please use the latest available 3 months if Oct to Dec is not available and specify which 3 months has been used.

The UHB provides, within the table below, the number of Dermatology, Gastroenterology and Rheumatology patients who were treated with Stelara and its biosimilars, for any disease, during the months of October, November and December 2024.

Drug Name	Oct 24	Nov 24	Dec 24
Ustekinumab (Stelara)	54	23	21
Ustekinumab (Biosimilars)	42	53	51